Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive Officer

[at noodls] – Rockville, MD, January 22, 2013 – Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage pharmaceutical company developing potential first in class oncology and CNS therapeutics, today announced … more

View todays social media effects on RNN

View the latest stocks trending across Twitter. Click to view dashboard

See who Rexahn is hiring next, click here to view